SLC5A2 and chronic kidney disease: This narrative review synthesizes emerging evidence for SGLT2 inhibitors in non-diabetic indications beyond heart failure and chronic kidney disease, with emphasis on biologic rationale, outcomes data, patient selection, safety in normoglycemic populations, and future research priorities.